Last updated on November 2017


Brief description of study


Detailed Study Description

EINSTEIN CHOICE is a phase II study designed to evaluate whether once-daily rivaroxaban in doses of 10mg or 20mg is superior to aspirin for the prevention of symptomatic recurrent DVT and/or PE in patients who have completed between six and 12 months of anticoagulant therapy. The study will include approximately 2,850 patients in 31 countries and currently is enrolling participants.

Clinical Study Identifier: TX5034

Contact Investigators or Research Sites near you

Start Over

Rebecca Palermo

UNC Rex Healthcare
Raleigh, NC USA